Nootropics A–Z

This is every compound we track, ordered as our evidence reference orders them, with four things attached to each: an evidence tier, a one-line verdict, and the population in which an effect was actually measured. Not one of them earns a strong rating for improving cognition in healthy adults — the honest top of this field is moderate, and several of the best-known names are here because they were studied properly and failed.

How to read this table

The fourth column is the one that does the work. Almost every claim you will see about these compounds is stated without a population — “improves memory,” “supports focus” — and stated that way it is false about every compound on this page. Attached to a population it can be true, and it is usually far narrower than the marketing implies: an effect found in Japanese adults aged 50 to 80 with mild cognitive impairment is not a result about a healthy 35-year-old, and an effect found in vegetarians is not a result about omnivores.

The tiers are defined in full in how we rate the evidence. In short: Strong means multiple RCTs or meta-analyses showing a consistent, clinically meaningful effect. Moderate means some RCTs with positive but limited, mixed or population-specific effects. Weak means mostly preclinical work, small studies, or inconsistent human data. None means the compound has been studied and largely failed, or has essentially not been studied in humans at all — two different situations that we distinguish in the verdict column. Avoid is reserved for ingredients that are not lawful US dietary ingredients; we will never recommend one.

Where a compound has its own page, the name links to it. Where it doesn’t, the row is the whole of what we currently publish on it, and we would rather say that than pad the catalogue.

Every compound, tiered

CompoundTierHonest verdictWhere an effect was actually seen
Citicoline (CDP-choline)ModerateBest evidence in vascular and age-related cognitive impairment; healthy-adult data thin and often industry-fundedOlder adults with age-associated memory impairment and vascular cognitive impairment. Not established in healthy high performers.
Alpha-GPCModerate Safety signalPositive in dementia at 1,200 mg/day, mostly alongside donepezil. A large Korean cohort found ~43% higher 10-year stroke risk — see the stroke signalPatients with mild-to-moderate Alzheimer’s or vascular dementia, especially as an add-on to donepezil. No convincing healthy-adult data.
Bacopa monnieriModerateA real but small effect on speed of attention and rate of memory acquisition, and only after about 12 weeks. GI side effects are commonHealthy adults across a broad age range taking a standardized extract for 12 weeks or more; some signal in older adults.
Lion’s maneWeakSeven small, short trials that disagree with each other; one found worse delayed recall than placebo in young adultsPossibly Japanese adults 50–80 with mild cognitive impairment, transiently. Null to negative in healthy young adults.
Ginkgo biloba (EGb 761)Moderate in dementia · None for preventionModest six-month benefit in dementia; little or no effect in MCI; two enormous prevention trials failedPeople with diagnosed dementia, over about six months, at 240 mg/day of EGb 761. Not MCI, not healthy adults, not prevention.
L-theanineModerate (acute)Small acute effects on reaction time and subjective calm. Not a memory agent, and not cumulativeHealthy adults, acutely, in the 0–2 hours after a dose. Some signal in anxiety-prone people and under acute stress.
Caffeine + L-theanineModerate (acute)The best-replicated acute combination in this file. Attention-switching accuracy SMD 0.33; digit vigilance accuracy SMD 0.20, at hour 2Healthy adults, for a few hours. Also acutely sleep-deprived young adults in a 2025 crossover trial.
Omega-3 (DHA/EPA)Moderate in subgroups · None for preventionThe classic epidemiology-versus-RCT split: excellent cohort data, trials that did not deliver in healthy older adults or established Alzheimer’sPeople with mild cognitive impairment, and people with low baseline omega-3 intake. Not the general older population.
Creatine monohydrateModerateMemory SMD around 0.29–0.31, which is small. EFSA rejected the cognitive claimAdults 66–76; vegetarians and vegans; sleep-deprived and acutely stressed people. Not healthy young omnivores.
Rhodiola roseaWeakThe fatigue trials are small and mostly low quality; cognition data are poor. Notable CYP3A4 and P-gp interaction riskPossibly shift workers and students under exam stress. Not established for cognition itself.
AshwagandhaModerate Safety signalA 2026 meta-analysis gives memory SMD 0.52, but the trial base is dominated by Indian studies. LiverTox likelihood score B for liver injuryGenerally healthy adults 18–75, mostly in India, over about eight weeks.
PhosphatidylserineModerate in older adults · Weak for soy formsThe original bovine-derived data does not transfer cleanly to the soy-derived material now sold. FDA allowed only a heavily qualified claimAdults over about 50 with age-associated memory impairment, particularly the poorest baseline performers.
Huperzine AModerate (China trials)A genuine acetylcholinesterase inhibitor — pharmacologically the same class as donepezil. Cochrane calls the evidence inadequate to recommend. We discuss it; we do not recommend itChinese patients with Alzheimer’s or vascular dementia, in low-quality trials. Not healthy adults.
VinpocetineAvoidFDA’s position is that it is not a lawful dietary ingredient, and it carries a 2019 FDA warning to women of childbearing ageNot applicable. We do not recommend it in any population.
Panax ginseng (Asian)WeakCochrane found no convincing cognitive-enhancing effect in healthy peoplePossibly people with subjective memory impairment or MCI, in Korean data. Not established in healthy adults.
American ginsengWeakSmall acute working-memory signals, largely from one research group and partly funded by the branded extract’s makerHealthy young adults, one to six hours after a single dose. Chronic-dosing evidence is minimal.
CurcuminWeak–ModerateOne notable 18-month trial of a bioavailable formulation; meta-analyses inconsistent and entirely dependent on which formulation was usedNon-demented middle-aged and older adults, in single small trials. Not people with established Alzheimer’s.
ResveratrolWeakThe cerebral blood flow changes replicate. The downstream cognitive benefit does notPostmenopausal women, on cerebrovascular and some cognitive measures. Nobody else, reliably.
Acetyl-L-carnitineModerate (older data)A positive 1990s meta-analysis, but the trials behind it are old, small and largely industry-runAdults with mild cognitive impairment and mild Alzheimer’s, over three months or more.
Magnesium L-threonateWeakAlmost entirely a rodent-derived rationale, plus a handful of small and mostly manufacturer-linked human trialsOlder adults with cognitive impairment in one small trial; possibly people with poor sleep. Not demonstrated in healthy adults.
Vitamin B12Moderate in deficiency · None when repleteThe cleanest “it depends entirely on your baseline” case here. Correcting deficiency matters enormously; supplementing replete people does nothing for cognitionPeople with a genuine deficiency — over-50s, vegans, people on metformin or long-term PPIs, and several clinical groups.
Vitamin B6WeakNo demonstrated cognitive benefit on its own; relevant only inside a homocysteine-lowering B-complex. Chronic high doses cause sensory peripheral neuropathyNo cognitive population on its own. The upper intake level is 100 mg/day and neuropathy has been reported below that with prolonged use.
Folate (B9)Moderate in deficiency · None in generalA meta-analysis of 11 trials in ~22,000 people found no effect on cognitive aging. VITACOG found something much narrower and more interestingAdults with MCI plus elevated homocysteine plus adequate omega-3 status. Not unselected older adults.
Vitamin DWeak · None for cognitionA strong observational link and null RCTs — VitaMIND and the Finnish D Trial both found no cognitive benefit. Correcting deficiency is still justified on other groundsNobody, for cognition, in randomized trials.
SaffronModerate (mild-moderate AD)Non-inferior to donepezil in small Iranian trials, with almost no independent replication outside that groupIranian adults with mild-to-moderate Alzheimer’s; adults with mild-to-moderate depression.
PQQWeakTwo or three small Japanese trials with mixed results, and a mitochondrial-biogenesis story built on cell culture. Heavily over-marketed relative to thatJapanese adults in small, industry-affiliated trials. No large independent trial exists.
CoQ10NoneEight human cognitive trials, many null. The NIH high-dose Parkinson’s trial was terminated for futilityNot cognition. The positive signals were in progressive supranuclear palsy and chronic fatigue syndrome.
NAD+ precursors (NR, NMN)WeakThe widest claim-to-evidence gap of any trending category. Blood NAD+ rises reliably; cognition does not followNobody yet — multiple trials found NAD+ elevation without functional benefit, and no adequate cognitive RCT exists.
TaurineWeakFew trials, short durations, no consistent effect — and most “alertness” data come from energy-drink studies where the caffeine is doing the workNo cognitive population established.
L-tyrosineModerate (under stress only)The clearest conditional compound here: it replenishes what depleting conditions deplete, and does nothing in their absenceHealthy young and middle-aged adults under acute stress, sleep loss, cold or multitasking load. One trial found it impaired response inhibition in healthy older adults.
SageWeak–ModerateGenuine cholinesterase inhibition and real acute trials, but tiny ones that are rarely replicated. Concentrated S. officinalis oil contains thujone and is not a casual purchaseHealthy older volunteers, acutely; and 42 adults with mild-to-moderate Alzheimer’s in one four-month trial.
Gotu kolaNoneA meta-analysis of 11 RCTs found no significant difference from placebo on any cognitive domain. Hepatitis case reports existNone. Its legitimate evidence is in venous insufficiency and wound healing, not cognition.
Noopept (omberacetam)AvoidA Russian prescription drug, and not a lawful US dietary ingredientNot applicable. We do not recommend it in any population.
RacetamsAvoidPiracetam, aniracetam, oxiracetam, phenylpiracetam, pramiracetam — not lawful US dietary ingredients; FDA has issued warning letters on that basisNot applicable. We do not recommend them in any population.
Caffeine (alone)Strong for alertness · None for memoryThe honest baseline every other compound here should be judged against. It works — for vigilance, not for learningHealthy adults, for vigilance, sustained attention and reaction time. In habitual users much of the apparent benefit is reversal of overnight withdrawal.
Daily multivitamin-mineralModerate, approaching strong in 65+COSMOS is the only large, multi-year, replicated positive cognitive result in this entire field — and it was a supermarket multivitamin. Boring, cheap, and the most under-covered result in the nicheOlder US adults over three years, with larger benefits in those with a cardiovascular disease history.
Cocoa flavanolsNoneTested properly inside COSMOS and failed, in the same trial where the multivitamin arm succeededNobody. A possible signal survives only in the subgroup with low baseline dietary flavanol intake — hypothesis-generating, nothing more.
Apoaequorin (Prevagen)NoneAn orally administered protein, digested to amino acids like any other. In December 2024 a federal court ordered the marketer to stop the memory claimsNone.
PhenibutAvoidFDA states it is not a dietary ingredient. Dependence and a severe withdrawal syndrome are well documented — the most dangerous item commonly sold in this categoryNot applicable. We do not recommend it in any population.
Uridine monophosphateWeakThe synaptogenesis research behind it is genuine but mostly rodent, and it was developed clinically as part of a medical-food matrix rather than as a standalone capsuleVery early or prodromal Alzheimer’s, within the full Souvenaid matrix. No adequate standalone trial in healthy adults exists.

What this table is not

It is not a shopping list, and the tiers are not scores to be added up. A moderate tier means the human evidence exists and is limited, not that the compound will do something for you — most of these moderates are moderate in a population you are probably not in. It is not a ranking either: caffeine sits at the top of the alertness column and is worthless for memory, which makes it better than most of this list at one job and irrelevant at another. And it is not permanent. Tiers move when trials publish, in both directions, and the date at the top of this page is when we last worked through it.

Before you use any of this to buy something, two habits are worth more than the table itself: check the label against the proprietary blend trick and the nine red-flag ingredients, and check your prescriptions against the interaction guide. Doses actually used in trials are on the individual pages, not here.

The one formula in our audit that publishes its doses
Neuro-Thrive

Neuro-Thrive is the only product in our audit that publishes a complete dose panel: vitamin D3 20 mcg, niacin 8 mg, vitamin B6 5 mg, bacopa monnieri 300 mg standardized to 50% bacosides, alpha-GPC 150 mg, GABA 100 mg and PQQ 10 mg. The bacopa is the actual trial dose rather than a symbolic pinch. Two things must be said before you consider it. Its PQQ is 10 mg, where the BioPQQ cognitive trial the category leans on (Nakano et al., 41 healthy elderly, 12 weeks) used 20 mg/day — that is half. And it contains alpha-GPC, which a large Korean cohort study associated with roughly 43% higher 10-year stroke risk, with a dose-response gradient; anyone on anticoagulants or with a cardiovascular or cerebrovascular history should talk to a clinician before taking it, and we would rather you read what that study found first.

We earn a commission if you buy through this link. It costs you nothing extra and it does not change what we write.

Full Neuro-Thrive review: doses, price, guarantee →

Check the current price →

Related reading

More compound and product guides

Product reviews

These statements have not been evaluated by the Food and Drug Administration. Nothing here is intended to diagnose, treat, cure or prevent any disease.

This article is information, not medical advice. Talk to a doctor or pharmacist about your own situation, especially if you take prescription medication.